Persimmon PLC (PSN)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 1,321.50 |
|---|---|
| 52-week range | 947.40 – 1,552.00 |
| Return, 1 month / 3 months | +16.3% / +20.7% |
| Return, 1 year / 3 years | +11.1% / +54.4% |
| Trend | Uptrend |
| RSI (14) | 68 |
| Volatility (1 year) | 36.2% |
| Worst drawdown (1 year) | -34.1% |
| Average daily value traded | 2,482.25M GBX |
| Dividend yield | 4.5% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Persimmon is a British housebuilder based in York. It builds new homes for private buyers and also provides affordable housing for housing associations and local authorities. Its brands include Charles Church, and its developments range from family houses to apartments in towns and suburbs across Britain. The company handles land acquisition, planning, construction and the sale of completed homes, and it also offers related services such as part-exchange and mortgage advice to its customers.
Persimmon PLC trades under the code PSN on the London Stock Exchange in UK, with its price quoted in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Persimmon PLC (PSN) trades on the London Stock Exchange in UK. It last closed at GBX 1,321.50 on 27 October 2026.
Its price-based Market X-Ray is 66 out of 100 (a fair price profile), ranking 855 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.1% and over the last three months it rose 20.7%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 14.9% | ||
| From 52-week high | -14.4% | ||
| Momentum | 71 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 20.7% | ||
| 6-month return | 28.2% | ||
| 12-month return, skipping the last month | -4.5% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 36.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -34.1% | ||
| Liquidity | 98 · Strong | Trades actively. | |
| Average daily value traded | 2,482.25M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | 56 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 4.5% | ||
| Years with dividends | 5 |
Strengths
- Momentum: Rising faster than most stocks on this exchange.
- Liquidity: Trades actively.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | +16.3% |
| 3 months | +20.7% |
| 6 months | +28.2% |
| 1 year | +11.1% |
| 3 years | +54.4% |
| 5 years | −33.9% |
Signals
| 50-day / 200-day average | 1,181.51 / 1,150.38 |
|---|---|
| Golden / death cross (60 days) | Golden, 11 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 36.67 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 15 Oct 2026 | GBP 0.2000 |
| 18 Jun 2026 | GBP 0.4000 |
| 16 Oct 2025 | GBP 0.2000 |
| 19 Jun 2025 | GBP 0.4000 |
| 17 Oct 2024 | GBP 0.2000 |
| 20 Jun 2024 | GBP 0.4000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.